Research & Development
Promis Diagnostics nabs FDA breakthrough device designation for bladder cancer test
The EarlyTect BCD test qualitatively detects an epigenetic biomarker, PENK methylation, associated with bladder cancer in the urine DNA of patients with hematuria.
April 28, 2023
Bladder cancer biomarker signature could identify likely responders to checkpoint inhibitors
A diagnostic tool that identifies the patients most likely to respond to checkpoint inhibitors could enable physicians to determine the best treatment for each individual.
April 27, 2023
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
The study, which will enroll more than 1,000 participants, aims to evaluate the noninvasive, qPCR assay which detects two DNA methylation biomarkers in urine specimens from patients suspected of having bladder cancer.
November 23, 2022
Nucleix announces CLIA certification, CAP accreditation for San Diego laboratory
Nucleix announced that it has received CLIA certification and CAP accreditation for its San Diego-based clinical laboratory.
October 19, 2022
Predicine to present posters on liquid biopsy tech at ESMO
Predicine's liquid biopsy portfolio includes assays that provide translational insights to aid in potential cancer therapeutic strategies.
September 8, 2022
Nanostics launches bladder cancer study
Its ClarityDX bladder test uses extracellular vesicle detection technology and machine-learning model analysis to identify the most potent disease predictors for the early detection of bladder cancer.
July 19, 2022
Nucleix expands EU label for bladder cancer test
Initially, the technology was indicated for the monitoring of tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
June 21, 2022
Nonagen Bioscience secures CE Mark for bladder cancer test
The urine test detects 10 biomarkers associated with bladder cancer, the company said.
June 16, 2022
Paige, Janssen collaborating on AI-based bladder cancer test
Developed by Janssen, the test is a first-of-its-kind screening tool to predict the occurrence of actionable genomic alterations, Paige said.
June 14, 2022
Bio-Techne, Nonangen enter into agreement for Oncuria
The companies said they are targeting the last quarter of calendar year 2022 to make Oncuria available as a laboratory-developed test.
May 12, 2022
Guardant highlights data on multicancer test at AACR 2022
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
ASCO study touts data from bladder cancer clinical trial
The identification of a biomarker for predicting bladder cancer survival comes out the secondary part of the S1314 clinical trial, which measured long-term survival data in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery.
February 13, 2022
Page 1 of 2